Articles related to GLYCEMIC CONTROL

Let’s delve into the groundbreaking application of endoscopic electroporation and semaglutide that’s changing the game in diabetes management. First off, the EMINENT study is unveiling a revolutionary approach in treating type 2 diabetes. This method combines endoscopic electroporation, known as ReCET, with the medication semaglutide. The main goal is to reduce or potentially eliminate the need for insulin, revolutionizing glycemic control. The innovative ReCET procedure employs electroporation to ablate the superficial layer of mucosa in the small intestine. Researchers hope that by rejuvenating the duodenal lining and employing a GLP-1 receptor agonist, they could address insulin resistance, the fundamental problem in type 2 diabetes. Interestingly, ReCET doesn’t use extreme temperatures to ablate intestinal tissue. Rather, it uses a pulsed electric field, yielding precise control and limited depth of penetration. This method disrupts the cellular membrane of the mucosa and superficial submucosa, triggering natural cell death within a day, thereby significantly minimizing the risk of complications. A single-arm pilot study conducted as part of EMINENT involved 14 patients with type 2 diabetes using long-acting basal insulin. All patients underwent the ReCET procedure and started on semaglutide two weeks later. Researchers noted the feasibility and safety of ReCET, with a 100% success […]

In a study including 73 meta-analyses and 8,601 unique articles, sugar consumption was associated with 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes. Endocrine/metabolic outcomes included weight gain, ectopic fat accumulation, obesity, and cardiovascular disease, which were largely attributed to excessive consumption of fructose containing sugars.

In a study of patients with DM2, 75 years old and over, continuous glucose monitoring revealed that 65% had glucose level two times below range (<54 mg/dL during ≥15 consecutive minutes) between midnight and 6 a.m. Fewer than half of the patients detected the hypoglycemic episode via self-monitoring. Because hypoglycemia episodes are associated with long-term complications, continuous glucose monitoring (CGM) could be used to improve care in these patients.

Getting a handle on the biochemical processes that govern how food is broken down and used within the body can be a daunting task for many, and even for those who understand it, monitoring with technology isn’t always possible. This is where Levels come into play. An instant metabolic analysis just a few hours after eating is only the beginning of the Levels experience; the app focuses on four major blood glucose levers in a gamified experience: diet, exercise, stress, and sleep. Dr. Lauren Kelley-Chew, Levels’ Head of Clinical Product, discusses all of this and more.

The study was conducted while GLP-1 RAs and SGLT-2 inhibitors were still considered second-line therapies; however, in a 2022 Consensus Report, the American Diabetes Association and the European Association for the Study of Diabetes recommended these medications as first-line therapy for people with type 2 diabetes who have or are at high risk of certain complications such as heart failure, CKD, and atherosclerotic cardiovascular disease (ASCVD). Are the medications’ price tag keeping people away?

Whether prescribing them for diabetes or weight loss, what factors should you consider when choosing among the seven approved GLP-1 agonist formulations? This concise review highlights the variables.